Ribomic Inc. announced that first patient of Cohort 2 has been enrolled and treated with RBM-007 for the company's phase I/IIa trial for the treatment of exudative age-related macular degeneration (AMD) in the United States. Upon completion of the RBM-007 injection by all 3 subjects in Cohort 1, the external safety review team assessed them and recommended to proceed to Cohort 2 (the cohort with next dose) since no safety concerns were raised in any of the Cohort 1 subjects. This PI/IIa trial is an open label, non-controlled, dose-escalating study assessing mainly the safety and tolerability of a single intravitreal injection of RBM-007 in approximately nine subjects.